UPXI · Upexi, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2024-03-12 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
64,150 |
| 2024-03-11 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
13,623 |
| 2024-03-05 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
103,013 |
| 2023-12-15 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
4,535 |
| 2023-12-14 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
8,381 |
| 2023-12-07 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
90,001 |
| 2023-12-05 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
19,296 |
| 2023-12-04 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
34,178 |
| 2023-11-15 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock Warrants
|
375,000 |
| 2023-05-22 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
22,776 |
| 2023-03-17 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
4,095 |
| 2023-03-16 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
4,572 |
| 2023-03-15 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
4,334 |
| 2022-12-16 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
4,578 |
| 2022-12-15 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,725 |
| 2022-12-14 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
10,000 |
| 2022-12-09 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
12,000 |
| 2022-12-01 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
18,475 |
| 2022-09-30 | Salkind Gene |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option Grant (right to buy) (Direct)
The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. |
Stock Option Grant (right to buy)
|
50,000 |
| 2022-09-30 | Williams Thomas Charles |
Director |
Award↑
Filing footnotes — Stock Option Grant (right to buy) (Direct)
The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. |
Stock Option Grant (right to buy)
|
50,000 |
| 2022-09-30 | Dugan Lawrence |
Director |
Award↑
Filing footnotes — Stock Option Grant (right to buy) (Direct)
The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. |
Stock Option Grant (right to buy)
|
50,000 |
| 2021-07-21 | Salkind Gene |
Director, 10% Owner |
Award↑
Filing footnotes — Option Grant (Direct)
50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. |
Option Grant
|
50,000 |
| 2021-07-21 | MARSHALL ALLAN |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Option Grant (Direct)
1,250,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. |
Option Grant
|
1,250,000 |
| 2021-07-21 | Norstrud Andrew James |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Option Grant (Direct)
200,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. |
Option Grant
|
200,000 |
| 2021-07-21 | Dugan Lawrence |
Director |
Award↑
Filing footnotes — Option Grant (Direct)
50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. |
Option Grant
|
50,000 |
| 2021-07-21 | Williams Thomas Charles |
Director |
Award↑
Filing footnotes — Option Grant (Direct)
50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. |
Option Grant
|
50,000 |